The study of fibroblast growth factor-2, sulfated glycosaminoglycans and oxyproline with mitral valve prolapse in combination with type 1 diabetes mellitus

Keywords: mitral valve prolapse, diabetes mellitus, fibroblast growth factor-2, glycosaminoglycans, free and peptide-bound oxyproline

Abstract

The aim. The aim of the study was to conduct a comparative analysis of fibroblast growth factor-2, the total content and fractions of sulfated glycosoaminoglycans as well as free and peptide-bounding oxyproline as the markers of connective tissue metabolism in young patients with mitral valve prolapse, type 1 diabetes mellitus and the combination of both indications.

Materials and methods. 93 patients between 19 and 33 years old with either mitral valve prolapse, or type 1 diabetes or the combination of both indications were examined. Group 1 was represented by 36 patients with the monomorbid type 1 diabetes mellitus. Group 2 consisted of 33 patients with type 1 diabetes mellitus and mitral valve prolapse. The comparison group included 24 people with diagnosed mitral valve prolapse. The concentration of fibroblast growth factor-2 in blood plasma was determined by the enzyme immunoassay using a Quantikine reagent kit (Human FGF basic Immunoassay), manufactured by R&D Systems, Inc. (USA) and expressed in pg/ml. The total content and fractions of glycosaminoglycans in blood serum were determined by the method of N. G. Stern et al. and expressed in units of optical density. The level of free and peptide-bounding oxyproline in blood serum were determined by the method of P. N. Sharaev and expressed in µmol/L.

Results. Fibroblast growth factor-2 was higher in group 2, where it was 23.7±0.25 pg/ml compared to the control group – 14.20±0.22 pg/ml (p <0.01). There was also a significant difference in the levels of fibroblast growth factor-2 between groups 1 where it equaled 15.33±0.24 pg/ml and 2 – 23.71±0.25 pg/ml (p<0.01). The total content of glycosaminoglycans in comparison with the control group, where it was equal to 9.7±0.62 odu, was higher in all groups of patients: in group 1 it was 12.07±1.04 odu, in the comparison group it was 11.75±0.83 odu, in the group with the combined pathology it was 13.32±1.59 odu (p<0.05). The values of glycosaminoglycans II fraction, were higher in group 2 – 4.96±0.59 odu. The level of peptide-bound oxyproline, just as the level of free oxyproline, significantly increased in patients with comorbid pathology in group 2, compared to the control group: 16.06±1.54 µmol/l versus 8.7±0.81 µmol/l (p<0.01) respectively.

Conclusions. The values of fibroblast growth factor-2, glycosaminoglycans II fraction, free and peptide-bound oxyproline were significantly higher in patients with diabetes mellitus and mitral valve prolapse in comparison with the control group. Fibroblast growth factor-2 was higher in patients with comorbid pathology compared to the monomorbid diabetes patients.

Downloads

Download data is not yet available.

Author Biographies

Olena Nikolenko, V. N. Karazin Kharkiv National 
University

Department of General Practice

Oleksiy Korzh, Kharkiv Medical Academy of Postgraduate Education

Department of General Practice

References

Pavlov, S. B., Pavlova, G. B. (2016). Study the role of intercellular mediators in the metabolism of connective tissue in children with cardiomyopathy and osteopeny. Journal of Education, Healthand Sport, 6 (9), 902–916. doi: http://dx.doi.org/10.5281/zenodo.163528

Martynov, A., Nechaeva, G. (2018). Guidelines of the Russian scientific medical society of internal medicine on the diagnosis, treatment and rehabilitation of patients with the connective tissue dysplasia (first edition). Medical News of the North Caucasus, 13 (1-2), 137–209. doi: http://doi.org/10.14300/mnnc.2018.13037

Khvysyuk, O. N., Pavlov, S. B., Pavlova, G. B. (2016). On the question of the role of the functional state of connective tissue in the implementation of the systemic response to damage. Problems of continuous medical education and science, 3, 55–61.

Pavlov, S. B., Zukow, W. (2016). Violation of collagen metabolism in the development of renal scarring in patients with chronic pyelonephritis. Journal of Education, Health and Sport, 6 (6), 263–278. doi: http://dx.doi.org/10.5281/zenodo.55365

Zakhvatov, A. N., Tarasova, T. V., Avanesov, A. M., Zakharkin, I. A., Khaidar, D. A., Chekmaeva, A. A., Sermina, T. A. (2018). Korrektsiia narushenii obmena kollagena pri artrite posttravmaticheskogo geneza. Puls, 20 (12), 193–197.

Arsentev, V. G., Sereda, Iu. V., Tikhonov, V. V. (2011). Displazii soedinitelnoi tkani – konstitutsionalnaia osnova poliorgannykh narushenii u detei i podrostkov. Pediatriia. Zhurnal im. G. N. Speranskogo, 90 (5), 54−57.

Zimering, M. B., Anderson, R. J., Ge, L., Moritz, T. E., Duckworth, W. C. (2013). Basic fibroblast growth factor predicts cardiovascular disease occurrence in participants from the veterans affairs diabetes trial. Front Endocrinol, 4. doi: http://doi.org/10.3389/fendo.2013.00183

Althunayyan, A., Petersen, S. E., Lloyd, G., Bhattacharyya, S. (2018). Mitral valve prolapse. Expert Review of Cardiovascular Therapy, 17 (1), 43–51. doi: http://doi.org/10.1080/14779072.2019.1553619

Mecarocci V., Mori F. (2016). Long-term outcome of primary mitral valve prolapse: results from a population of 250 patients referred to a tertiary cardiovascular center. European Heart Journal – Cardiovascular Imaging, 17 (2), 29–37. doi: http://doi.org/10.1093/ehjci/jew236.001

International classification of diseases 10th revision (ICD-10). Available at: https://icd.who.int/browse10/2019/en

Bayer-Topilsky, T., Suri, R. M., Topilsky, Y., Marmor, Y. N., Trenerry, M. R., Antiel, R. M. et. al. (2016). Mitral Valve Prolapse, Psychoemotional Status, and Quality of Life: Prospective Investigation in the Current Era. The American Journal of Medicine, 129 (10), 1100–1109. doi: http://doi.org/10.1016/j.amjmed.2016.05.004

Bui, A. H., Roujol, S., Foppa, M., Kissinger, K. V., Goddu, B., Hauser, T. H. et. al. (2016). Diffuse myocardial fibrosis in patients with mitral valve prolapse and ventricular arrhythmia. Heart, 103 (3), 204–209. doi: http://doi.org/10.1136/heartjnl-2016-309303

Nalliah, C. J., Mahajan, R., Elliott, A. D., Haqqani, H., Lau, D. H., Vohra, J. K. et. al. (2018). Mitral valve prolapse and sudden cardiac death: a systematic review and meta-analysis. Heart, 105 (2), 144–151. doi: http://doi.org/10.1136/heartjnl-2017-312932

Perazzolo Marra, M., Basso, C., De Lazzari, M., Rizzo, S., Cipriani, A., Giorgi, B. et. al. (2016). Morphofunctional Abnormalities of Mitral Annulus and Arrhythmic Mitral Valve Prolapse. Circulation: Cardiovascular Imaging, 9 (8). doi: http://doi.org/10.1161/circimaging.116.005030

Rubanenko, A. O., Diachkov, V. A., Shchukin, Yu. V., Rubanenko, O. A., Yurchenko, I. N. (2019). Acquired valvular heart diseases: clinical picture and diagnostics. Cardiology: News, Opinions, Training, 7 (3), 26–36. doi: http://doi.org/10.24411/2309-1908-2019-13003

Clavel, M.-A., Mantovani, F., Malouf, J., Michelena, H. I., Vatury, O., Jain, M. S. et. al. (2015). Dynamic Phenotypes of Degenerative Myxomatous Mitral Valve Disease. Circulation: Cardiovascular Imaging, 8 (5). doi: http://doi.org/10.1161/circimaging.114.002989

Kitkungvan, D., Nabi, F., Kim, R. J., Bonow, R. O., Khan, M. A., Xu, J. et. al. (2018). Myocardial Fibrosis in Patients With Primary Mitral Regurgitation With and Without Prolapse. Journal of the American College of Cardiology, 72 (8), 823–834. doi: http://doi.org/10.1016/j.jacc.2018.06.048

Alimova, I., Pashinskaya, N., Pleskachevskaja, T. (2016). Peculiarities of diabetes mellitus type 1 in children and adolescents against the background of connective tissue dysplasia. Medical News of the North Caucasus, 11 (2), 272–275. doi: http://doi.org/10.14300/mnnc.2016.11053

Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry tsukrovomu diabeti 1 typu u molodykh liudei ta doroslykh (2014). Nakaz MOZ Ukrainy No. 1021. 29.12.2014. Available at: https://ips.ligazakon.net/document/view/moz24121?an=7&ed=2014_12_29 Last accessed: 30.04.2020

Freed, L. A., Benjamin, E. J., Levy, D., Larson, M. G., Evans, J. C., Fuller, D. L. et. al. (2002). Mitral valve prolapse in the general population. The benign nature of echocardiography features in the Framingham Heart Study. Journal of the American College of Cardiology, 40 (7), 1298–1304. doi: http://doi.org/10.1016/s0735-1097(02)02161-7

Bonow, R. O., Carabello, B. A., Kanu, C. et. al. (2006). The mitral valve (MV) is situated within a fibrous annulus. Circulation, 114 (5), e84–231.

Shtern, M. R., Timoshenko, O. P., Leonteva, F. S., Kliueva, G. F. (1982). Pat. No. 960626 SU. MPK: G01N 33/48 (2006.01). Sposob opredeleniia glikozaminoglikanov v syvorotke krovi. No. 2998857. declareted: 23.10.1980; published: 23.09.1982.

Sharaev, P. N. (1990). Metod opredeleniia svobodnogo i sviazannogo oksiprolina v syvorotke krovi. Laboratornoe delo, 5, 283–285.


👁 73
⬇ 69
Published
2021-03-16
How to Cite
Nikolenko, O., & Korzh, O. (2021). The study of fibroblast growth factor-2, sulfated glycosaminoglycans and oxyproline with mitral valve prolapse in combination with type 1 diabetes mellitus. EUREKA: Health Sciences, (2), 9-15. https://doi.org/10.21303/2504-5679.2021.001653
Section
Medicine and Dentistry